Fas/fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction

Journal of Investigative Dermatology

Volumn 134, Issue 11, 2014, Pages 2768-2775

  Yeh, Chun Nan ^a   Chung, Wen Hung ^a   Su, Shih Chi ^a   Chen, Yen Yang ^b   Cheng, Chi Tung ^a   Lin, Yen Ling ^c   Chang, Wan Chun ^c   Hui, Rosaline Chung Yee ^a   Chiang, Kun Chun ^a   Chen, Tsung Wen ^a   Jan, Yi Yin ^a   Chen, Chien Wei ^c   Chen, Ting Jui ^c,d   Yang, Chih Hsun ^a   Hung, Shuen Iu ^c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FAS ANTIGEN; FAS LIGAND; SUNITINIB; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLISTER; BLOOD LEVEL; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MAJOR CLINICAL STUDY; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RASH; SKIN BIOPSY; SKIN DISCOLORATION; SKIN MANIFESTATION; STOMATITIS; TREATMENT DURATION; ANIMAL; BIOPSY; BLOOD; C3H MOUSE; CHEMICALLY INDUCED; CHEMISTRY; CYTOLOGY; DISEASE MODEL; ERYTHEMA; FEMALE; FOOT; GENE EXPRESSION REGULATION; HAND; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; TIME; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD95; APOPTOSIS; BIOLOGICAL MARKERS; BIOPSY; CELL DEATH; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ERYTHEMA; FAS LIGAND PROTEIN; FEMALE; FOOT; GENE EXPRESSION REGULATION; HAND; HUMANS; INDOLES; KERATINOCYTES; MICE; MICE, INBRED C3H; PYRROLES; TIME FACTORS;

EID: 84908574875     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.218     Document Type: Article

References (38)

1. Adams VR, Leggas M (2007) Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 29:1338-53
2. Alderson MR, Armitage RJ, Maraskovsky E., et al (1993) Fas transduces activation signals in normal human T lymphocytes. J Exp Med 178:2231-5
3. Anderson R, Jatoi A, Robert C., et al (2009) Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs) Oncologist 14:291-302
4. Baker MB, Altman NH, Podack ER., et al (1996) The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 183:2645-56
5. Baris YS, Yildiz L, Senturk N., et al (2005) Fas (CD95) and bcl-2 expression in active skin lesions of Behcet?s disease. J Eur Acad Dermatol Venereol 19:569-72
6. Biancone L, Martino AD, Orlandi V., et al (1997) Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J Exp Med 186:147-52
7. Blanchet B, Saboureau C, Benichou AS., et al (2009) Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. Clin Chim Acta 404:134-39
8. Chen YY, Yeh CN, Cheng CT., et al (2011) Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World J Gastroenterol 17:2113-9
9. Cheng AL, Kang YK, Chen Z., et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
10. Choi HJ, Ku JK, Kim MY., et al (2006) Possible role of Fas/Fas ligand-mediated apoptosis in the pathogenesis of fixed drug eruption. Br J Dermatol 154:419-25
11. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-96
12. Chu TF, Rupnick MA, Kerkela R., et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-19
13. Chung WH, Hung SI, Yang JY., et al (2008) Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14:1343-50
14. Collins C, Wolfe J, Roessner K., et al (2005) Lyme arthritis synovial gammadelta T cells instruct dendritic cells via fas ligand. J Immunol 175:5656-65
15. Farley SM, Wood LJ, Iordanov MS (2011) An epidermotypic model of interface dermatitis reveals individual functions of fas ligand and gamma interferon in hypergranulosis, cytoid body formation, and gene expression. Am J Dermatopathol 33:244-50
16. Gan HK, Seruga B, Knox JJ (2009) Sunitinib in solid tumors. Expert Opin Investig Drugs 18:821-34
17. George S, Blay JY, Casali PG., et al (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45:1959-68
18. Gutierrez-Steil C, Wrone-Smith T, Sun X., et al (1998) Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L) J Clin Invest 101:33-9
19. Hohlbaum AM, Moe S, Marshak-Rothstein A (2000) Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 191:1209-20
20. Jacobi U, Waibler E, Schulze P., et al (2005) Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?. Ann Oncol 16:1210-1
21. Krensky AM, Clayberger C (2009) Biology and clinical relevance of granulysin. Tissue Antigens 73:193-8
22. Lacouture ME, Reilly LM, Gerami P., et al (2008) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19:1955-61
23. Lee JH, Chung YH, Kim JA., et al (2012) Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 119:136-42
24. Lee JH, Chung YH, Kim JA., et al (2013) Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 119:36-142
25. Lee WJ, Lee JL, Chang SE., et al (2009) Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 161:1045-51
26. Lipworth AD, Robert C, Zhu AX (2009) Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77:257-71
27. Manchen E, Robert C, Porta C (2011) Management of tyrosine kinase inhibitorinduced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol 9:13-23
28. Mrozek-Orlowski ME, Frye DK, Sanborn HM (1999) Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 26:753-62
29. Nardone B, Hensley JR, Kulik L., et al (2012) The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol 11:e61-5
30. Restifo NP (2000) Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 6:493-5
31. Sano S, Chan KS, Carbajal S., et al (2005) Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11:43-9
32. Sayama K, Yonehara S, Watanabe Y., et al (1994) Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes. J Invest Dermatol 103:330-4
33. Tsai KY, Yang CH, Kuo TT., et al (2006) Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 24:5786-8
34. Viard-Leveugle I, Bullani RR, Meda P., et al (2003) Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. J Biol Chem 278:16183-8
35. Viard I, Wehrli P, Bullani R., et al (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490-3
36. Viard-Leveugle I, Gaide O, Jankovic D., et al (2013) TNF-A and IFN-g are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol 133:489-98
37. Wang EC, Lee JS, Tan AW., et al (2011) Fas-ligand staining in non-drug- And drug-induced maculopapular rashes. J Cutan Pathol 38:196-201
38. Yang CH, Chuang CK, Hsieh JJ., et al (2010) Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma. Expert Opin Drug Saf 9:459-70